Tier 2 — strong

The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects

Satish Kumar Bedada, Prasad Neerati
European journal of clinical pharmacology 2018 74(1):91-97

Bibliography

PubMed
PMID 28983678
DOI
10.1007/s00228-017-2345-9
Funding
Indexed grant support: F.7-106/2007. BSR — University Grants Commission. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignOpen-label two-period sequential drug-interaction study
ModelHuman intervention research
Sample12 healthy volunteers
InterventionQuercetin 500 mg twice daily for 10 days; chlorzoxazone 250 mg as probe
DurationControl and supplementation phases
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2018, this source examined safety, interactions and special populations. Design: Open-label two-period sequential drug-interaction study. Sample/model: 12 healthy volunteers. The exposure or intervention was Quercetin 500 mg twice daily for 10 days; chlorzoxazone 250 mg as probe. Follow-up or treatment period: Control and supplementation phases.

Chlorzoxazone exposure and peak concentration increased, while metabolite formation decreased.

Probe-drug findings do not establish a therapeutic strategy for alcohol-related liver injury. Clinical adverse-event consequences and effects on other drugs were not tested.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Chlorzoxazone exposure and peak concentration increased, while metabolite formation decreased.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 mg twice daily for 10 days; chlorzoxazone 250 mg as probe; Control and supplementation phases.

What this study can and cannot tell us

  • Probe-drug findings do not establish a therapeutic strategy for alcohol-related liver injury. Clinical adverse-event consequences and effects on other drugs were not tested.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology